PE20080738A1 - Sistema de liberacion controlada y metodo para fabricarlo - Google Patents
Sistema de liberacion controlada y metodo para fabricarloInfo
- Publication number
- PE20080738A1 PE20080738A1 PE2007001080A PE2007001080A PE20080738A1 PE 20080738 A1 PE20080738 A1 PE 20080738A1 PE 2007001080 A PE2007001080 A PE 2007001080A PE 2007001080 A PE2007001080 A PE 2007001080A PE 20080738 A1 PE20080738 A1 PE 20080738A1
- Authority
- PE
- Peru
- Prior art keywords
- layer
- controlled release
- release system
- etilcellulose
- optionally
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Abstract
REFERIDA A UN SISTEMA DE LIBERACION CONTROLADA QUE COMPRENDE: a) UN MATERIAL DE NUCLEO QUE COMPRENDE UNO O MAS MODIFICAODRES DE pH, b) OPCIONALMENTE UNA CAPA AISLANTE, c) UNA PRIMERA CAPA QUE COMPRENDE UNO O MAS POLIMEROS INSOLUBLES EN AGUA, d) UNA SEGUNDA CAPA QUE COMPRENDE POR LO MENOS UNA SUSTANCIA ACTIVA QUE TIENE UNA SOLUBILIDAD DEPENDIENTE DEL pH, e) UNA TERCERA CAPA QUE COMPRENDE UNO O MAS POLIMEROS QUE TIENEN GRUPOS ANIONICOS O NO IONICOS Y f) OPCIONALMENTE UNA CUARTA CAPA. EL MODIFICADOR DE pH SE SELECCIONA DE ACIDOS ORGANICOS TAL COMO ACIDO ACETICO, ASCORBICO, ENTRE OTROS, UNA O MAS BASES, UNO O MAS TAMPONES TAL COMO CARBONATO DE CALCIO, FOSFATO DE CALCIO TRIBASICO, ENTRE OTROS Y MEZCLAS DE LOS MISMOS; DE PREFERENCIA EL POLIMERO INSOLUBLE EN AGUA ES ETILCELULOSA; EL POLIMERO DE LA TERCERA CAPA PUEDE SER ETILCELULOSA, HIDROXIPROPILMETILCELULOSA FTALATO, ENTRE OTROS; EL COMPUESTO ACTIVO ES FLIBANSERINA. TAMBIEN ESTA REFERIDA A UN METODO DE PREPARACION
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06017754 | 2006-08-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20080738A1 true PE20080738A1 (es) | 2008-08-05 |
Family
ID=38596345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2007001080A PE20080738A1 (es) | 2006-08-25 | 2007-08-13 | Sistema de liberacion controlada y metodo para fabricarlo |
Country Status (19)
Country | Link |
---|---|
US (1) | US8512748B2 (es) |
EP (1) | EP2056797A2 (es) |
JP (1) | JP5220746B2 (es) |
KR (1) | KR20090045945A (es) |
CN (2) | CN104721168A (es) |
AR (1) | AR062321A1 (es) |
AU (1) | AU2007287639A1 (es) |
BR (1) | BRPI0716436B8 (es) |
CA (1) | CA2661613C (es) |
CL (1) | CL2007002358A1 (es) |
CO (1) | CO6150131A2 (es) |
EA (1) | EA200900270A1 (es) |
IL (1) | IL197129A (es) |
MX (1) | MX2009002031A (es) |
NO (1) | NO20090100L (es) |
PE (1) | PE20080738A1 (es) |
TW (1) | TW200817053A (es) |
WO (1) | WO2008022932A2 (es) |
ZA (1) | ZA200810781B (es) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7183410B2 (en) * | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
US20030060475A1 (en) * | 2001-08-10 | 2003-03-27 | Boehringer Ingelheim Pharma Kg | Method of using flibanserin for neuroprotection |
US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
US20040048877A1 (en) * | 2002-05-22 | 2004-03-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions containing flibanserin |
US8679533B2 (en) * | 2002-07-25 | 2014-03-25 | Pharmacia Corporation | Pramipexole once-daily dosage form |
WO2005102342A1 (en) * | 2004-04-22 | 2005-11-03 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for the treatment of sexual disorders ii |
US20050239798A1 (en) * | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the treatment of premenstrual and other female sexual disorders |
US20060025420A1 (en) * | 2004-07-30 | 2006-02-02 | Boehringer Ingelheimn International GmbH | Pharmaceutical compositions for the treatment of female sexual disorders |
KR101052436B1 (ko) * | 2004-08-13 | 2011-07-29 | 베링거 인겔하임 인터내셔날 게엠베하 | 프라미펙솔 또는 약제학적으로 허용되는 이의 염을함유하는 연장 방출형 정제 제형, 이의 제조방법 및 이의용도 |
KR20070050081A (ko) * | 2004-08-13 | 2007-05-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 프라미펙솔 또는 약제학적으로 허용되는 이의 염을포함하는 연장 방출형 펠렛 제형, 이의 제조방법 및 이의용도 |
JP2008511569A (ja) * | 2004-09-03 | 2008-04-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 注意欠如活動過多障害の治療方法 |
WO2006096439A2 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
JP2008538741A (ja) * | 2005-03-04 | 2008-11-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 鬱病の治療用及び/又は予防用の医薬組成物 |
CA2599937A1 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders |
JP2008540356A (ja) * | 2005-05-06 | 2008-11-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 薬物乱用の治療方法 |
WO2006125041A1 (en) * | 2005-05-19 | 2006-11-23 | Boehringer Ingelheim International Gmbh | Method for the treatment of sexual dysfunctions due to medical conditions |
EP1888071A1 (en) * | 2005-05-19 | 2008-02-20 | Boehringer Ingelheim International GmbH | Method for the treatment of drug-induced sexual dysfunction |
JP2009503020A (ja) | 2005-08-03 | 2009-01-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 肥満症の治療におけるフリバンセリンの使用 |
JP2009513604A (ja) | 2005-10-29 | 2009-04-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体 |
WO2007090883A1 (en) * | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Extended release formulation |
WO2007090881A2 (en) * | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Modified release formulation |
PE20080090A1 (es) * | 2006-05-09 | 2008-03-14 | Boehringer Ingelheim Int | Flibanserina para el tratamiento de trastornos post-menopausicos del deseo sexual |
DE602007004615D1 (de) | 2006-06-30 | 2010-03-18 | Boehringer Ingelheim Pharma | Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen |
US20090318469A1 (en) * | 2006-07-14 | 2009-12-24 | Boehringer Ingelheim International Gmbh | Use of Flibanserin for the Treatment of Sexual Disorders in Females |
CL2007002214A1 (es) * | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
KR20090042967A (ko) | 2006-08-14 | 2009-05-04 | 베링거 인겔하임 인터내셔날 게엠베하 | 플리반세린 제형 및 이의 제조방법 |
AU2007287639A1 (en) | 2006-08-25 | 2008-02-28 | Boehringer Ingelheim International Gmbh | Controlled release system and method for manufacturing the same |
ATE524446T1 (de) | 2006-12-20 | 2011-09-15 | Boehringer Ingelheim Int | Sulfatierte benzimidazolon-derivate mit gemischter serotonin-rezeptor-affinität |
US8304601B2 (en) * | 2007-01-23 | 2012-11-06 | Keiko Fujikawa | Mouse model for eye disease |
PE20091188A1 (es) * | 2007-09-12 | 2009-08-31 | Boehringer Ingelheim Int | Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen |
EP2090297A1 (en) * | 2008-02-13 | 2009-08-19 | Boehringer Ingelheim International GmbH | Formulations of flibanserin |
CA2716642C (en) * | 2008-03-28 | 2017-02-28 | Boehringer Ingelheim International Gmbh | Method for manufacturing acid pellets |
CA2686480A1 (en) | 2008-12-15 | 2010-06-15 | Boehringer Ingelheim International Gmbh | New salts |
WO2011107427A1 (en) * | 2010-03-01 | 2011-09-09 | Ratiopharm Gmbh | Dabigatran etexilate-containing oral pharmaceutical composition |
WO2011127244A2 (en) * | 2010-04-09 | 2011-10-13 | Bristol-Myers Squibb Company | ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT |
WO2012006334A1 (en) | 2010-07-09 | 2012-01-12 | Synthes Usa, Llc | Self-detaching layer for easy implant removal |
AR086913A1 (es) * | 2011-06-14 | 2014-01-29 | Novartis Ag | 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas |
CA2876200A1 (en) * | 2012-06-14 | 2013-12-19 | Allied Blending & Ingredients, Inc. | Method of treating a divided cheese product for anticaking and compositions thereof |
US20130345262A1 (en) | 2012-06-25 | 2013-12-26 | Boehringer Ingelheim International Gmbh | Method for prevention of stroke |
EP2916824B1 (en) | 2012-11-12 | 2019-06-19 | New Jersey Institute of Technology | Pharmaceutical core-shell composite powder and processes for making the same |
EP2853260A1 (en) | 2013-09-27 | 2015-04-01 | ratiopharm GmbH | Pharmaceutical preparation comprising dabigatran etexilate bismesylate |
GB201416293D0 (en) | 2014-09-15 | 2014-10-29 | Solvotrin Therapeutics Ltd | Methods and preparations |
CA2966631A1 (en) | 2014-11-14 | 2016-05-19 | Gemphire Therapeutics Inc. | Processes and intermediates for preparing alpha, omega-dicarboxylic acid-terminated dialkane ethers |
EP3167879A1 (en) * | 2015-11-10 | 2017-05-17 | Evonik Technochemie GmbH | Gastric retention active delivery systems |
US9668991B1 (en) * | 2015-12-09 | 2017-06-06 | International Business Machines Corporation | SCFA colonic composition |
EP3429560A1 (en) * | 2016-03-15 | 2019-01-23 | Solvotrin Therapeutics Ltd. | Compositions and methods for increasing iron intake in a mammal |
US11033039B2 (en) | 2017-04-26 | 2021-06-15 | Allied Blending LP | Methods for treating a divided cheese product and compositions thereof |
US20190008779A1 (en) * | 2017-05-11 | 2019-01-10 | Gemphire Therapeutics Inc. | Gemcabene compositions and methods of use thereof |
CN110251475B (zh) * | 2019-07-25 | 2021-07-16 | 沈阳信康药物研究有限公司 | 一种帕利哌酮片剂及其制备方法 |
US10624361B1 (en) | 2019-09-20 | 2020-04-21 | Allied Blending LP | Methods for treating a divided cheese product and compositions thereof |
US20220347103A1 (en) * | 2019-09-27 | 2022-11-03 | Hercules Llc | Titanium dioxide free white film coating composition, process for preparing the same and method of use thereof |
Family Cites Families (129)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3096248A (en) * | 1959-04-06 | 1963-07-02 | Rexall Drug & Chemical Company | Method of making an encapsulated tablet |
US3406178A (en) * | 1964-02-04 | 1968-10-15 | Monsanto Chem Australia Ltd | Preparation of 2-substituted benzimidazoles |
US3362956A (en) * | 1965-08-19 | 1968-01-09 | Sterling Drug Inc | 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines |
US4200641A (en) * | 1976-12-21 | 1980-04-29 | Janssen Pharmaceutica, N.V. | 1-[(Heterocyclyl)-alkyl]-4-diarylmethoxy piperidine derivatives |
DK251079A (da) | 1978-06-20 | 1979-12-21 | Synthelabo | Fremgangsmaade til fremstilling af phenylpiperazinderivater |
DE3000979A1 (de) * | 1980-01-12 | 1981-07-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue dipyridamol-retardformen und verfahren zu ihrer herstellung |
IT1176613B (it) * | 1984-08-14 | 1987-08-18 | Ravizza Spa | Derivati piperazinici farmacologicamente attivi e processo per la loro preparazione |
IE58370B1 (en) | 1985-04-10 | 1993-09-08 | Lundbeck & Co As H | Indole derivatives |
GB8607294D0 (en) * | 1985-04-17 | 1986-04-30 | Ici America Inc | Heterocyclic amide derivatives |
DE3620643A1 (de) | 1985-06-22 | 1987-01-22 | Sandoz Ag | Thiazole, ihre herstellung und verwendung |
NL8601494A (nl) | 1985-06-22 | 1987-01-16 | Sandoz Ag | Thiazolen, hun bereiding en farmaceutische preparaten die ze bevatten. |
GB8601160D0 (en) * | 1986-01-17 | 1986-02-19 | Fujisawa Pharmaceutical Co | Heterocyclic compounds |
US5036088A (en) * | 1986-06-09 | 1991-07-30 | Pfizer Inc. | Antiallergy and antiinflammatory agents, compositions and use |
JPH0784462B2 (ja) * | 1986-07-25 | 1995-09-13 | 日清製粉株式会社 | ベンゾイミダゾ−ル誘導体 |
US4968508A (en) * | 1987-02-27 | 1990-11-06 | Eli Lilly And Company | Sustained release matrix |
US4792452A (en) * | 1987-07-28 | 1988-12-20 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
GB8830312D0 (en) | 1988-12-28 | 1989-02-22 | Lundbeck & Co As H | Heterocyclic compounds |
US4954503A (en) * | 1989-09-11 | 1990-09-04 | Hoechst-Roussel Pharmaceuticals, Inc. | 3-(1-substituted-4-piperazinyl)-1H-indazoles |
PT98628A (pt) | 1990-08-09 | 1992-06-30 | Massachusetts Inst Technology | Processo de composicoes farmaceuticas a base de por exemplo sertralina |
DE69129839T2 (de) | 1990-08-24 | 1999-02-11 | Shinetsu Chemical Co | Beschichtungsbase für einen pharmazeutischen film und verfahren zur herstellung derselben |
NZ241613A (en) * | 1991-02-27 | 1993-06-25 | Janssen Pharmaceutica Nv | Highlighting intagliations in tablets |
SE9100860D0 (sv) * | 1991-03-22 | 1991-03-22 | Kabi Pharmacia Ab | New use |
FR2675800A1 (fr) | 1991-04-26 | 1992-10-30 | Rhone Poulenc Rorer Sa | Derives heterocycliques antiserotonines leur preparation et les medicaments les contenant. |
IT1251144B (it) * | 1991-07-30 | 1995-05-04 | Boehringer Ingelheim Italia | Derivati del benzimidazolone |
US5407686A (en) * | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
US5225417A (en) * | 1992-01-21 | 1993-07-06 | G. D. Searle & Co. | Opioid agonist compounds |
US5492907A (en) * | 1992-12-09 | 1996-02-20 | The United States Of America As Represented By The Department Of Health & Human Services | Antipsychotic composition and method of treatment |
FR2707294B1 (fr) | 1993-07-06 | 1995-09-29 | Pf Medicament | Nouveaux dérivés de la 3,5-dioxo-(2H,4H)-1,2,4-triazine, leur préparation et leur application en thérapeutique humaine. |
DE4332394A1 (de) * | 1993-09-23 | 1995-03-30 | Falk Pharma Gmbh | Budesonid-Pellets mit kontrolliertem Freigabeprofil und Verfahren zu ihrer Herstellung |
GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
CA2192975C (en) | 1994-06-14 | 1999-09-21 | Anton F. Fliri | Benzimidazolone derivatives |
ATE227574T1 (de) | 1994-08-23 | 2002-11-15 | Smithkline Beecham Plc | Verbesserte,ibuprofen und codein enthaltende, pharmazeutische zusammensetzungen |
ATE247114T1 (de) | 1994-09-12 | 2003-08-15 | Lilly Co Eli | Serotonergische modulatoren |
FR2727682A1 (fr) * | 1994-12-02 | 1996-06-07 | Pf Medicament | Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament |
US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
US5883094A (en) * | 1995-04-24 | 1999-03-16 | Pfizer Inc. | Benzimidazolone derivatives with central dopaminergic activity |
US5854290A (en) * | 1995-09-21 | 1998-12-29 | Amy F. T. Arnsten | Use of guanfacine in the treatment of behavioral disorders |
US6083947A (en) * | 1996-01-29 | 2000-07-04 | The Regents Of The University Of California | Method for treating sexual dysfunctions |
GB9613423D0 (en) | 1996-06-26 | 1996-08-28 | Lilly Industries Ltd | Pharmaceutical compounds |
US5916916A (en) * | 1996-10-10 | 1999-06-29 | Eli Lilly And Company | 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods |
AU5179898A (en) * | 1996-11-06 | 1998-05-29 | Sharmatek, Inc. | Delayed delivery system for acid-sensitive drugs |
JP2001504851A (ja) * | 1996-12-02 | 2001-04-10 | メルク シヤープ エンド ドーム リミテツド | 性的機能不全の治療のためのnk−1受容体拮抗薬の使用 |
US5859246A (en) | 1997-01-30 | 1999-01-12 | Neurogen Corporation | 1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands |
GB9706089D0 (en) | 1997-03-24 | 1997-05-14 | Scherer Ltd R P | Pharmaceutical composition |
US20040023948A1 (en) * | 1997-03-24 | 2004-02-05 | Green Richard David | Fast-dispersing dosage form containing 5-HT1 agonists |
SG108292A1 (en) * | 1997-06-11 | 2005-01-28 | Procter & Gamble | Film-coated tablet for improved upper gastrointestinal tract safety |
ATE241341T1 (de) * | 1997-09-10 | 2003-06-15 | Takeda Chemical Industries Ltd | Stabilisierte pharmazeutische zusammensetzung |
SE9703375D0 (sv) | 1997-09-18 | 1997-09-18 | Astra Ab | A new combination |
CH692199A8 (fr) * | 1997-10-09 | 2002-06-14 | Cermol S.A. | Composes pyridiques et compositions pharmaceutique |
JP3724157B2 (ja) * | 1997-10-30 | 2005-12-07 | コニカミノルタホールディングス株式会社 | 映像観察装置 |
FR2775188B1 (fr) * | 1998-02-23 | 2001-03-09 | Lipha | Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption |
WO1999059584A1 (en) | 1998-05-20 | 1999-11-25 | Schering Corporation | Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction |
WO1999059593A1 (en) | 1998-05-21 | 1999-11-25 | Eli Lilly And Company | Combination therapy for treatment of depression |
US20020151543A1 (en) * | 1998-05-28 | 2002-10-17 | Sepracor Inc. | Compositions and methods employing R (-) fluoxetine and other active ingredients |
US6068846A (en) * | 1998-08-05 | 2000-05-30 | Melaleuca, Incorporated | Methods and materials for treating depression and mood disorder |
EP0982030A3 (en) * | 1998-08-17 | 2000-05-10 | Pfizer Products Inc. | 2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives as 5ht 1a ligands |
UA67802C2 (uk) | 1998-10-23 | 2004-07-15 | Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. | Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції |
AU1738900A (en) | 1998-11-19 | 2000-06-05 | Nortran Pharmaceuticals Inc. | Serotonin ligands as pro-erectile compounds |
US6680071B1 (en) * | 1999-03-03 | 2004-01-20 | R. P. Scherer Technologies, Inc. | Opioid agonist in a fast dispersing dosage form |
AU4465200A (en) | 1999-04-16 | 2000-11-02 | Dr. Reddy's Research Foundation | Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them |
WO2000064441A2 (en) | 1999-04-28 | 2000-11-02 | Respiratorius Ab | Compound for use as a medicament for treatment of disorders involving bronchocontraction |
IT1312310B1 (it) | 1999-05-07 | 2002-04-15 | Recordati Ind Chimica E Farma | Uso di antagonisti selettivi del recettore adrenergico a 1b per ilmiglioramento della disfunzione sessuale |
US6579968B1 (en) | 1999-06-29 | 2003-06-17 | Palatin Technologies, Inc. | Compositions and methods for treatment of sexual dysfunction |
US6346548B1 (en) * | 1999-08-16 | 2002-02-12 | Cephalon, Inc. | Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue |
IT1313625B1 (it) * | 1999-09-22 | 2002-09-09 | Boehringer Ingelheim Italia | Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina. |
PT1257277E (pt) * | 2000-02-24 | 2005-09-30 | Pharmacia & Upjohn Co Llc | Novas combinacoes de farmacos |
EA200201119A1 (ru) | 2000-06-28 | 2003-06-26 | Пфайзер Продактс Инк. | Лиганды меланокортиновых рецепторов |
US6521623B1 (en) * | 2000-09-19 | 2003-02-18 | Boehringer Ingelheim Pharma Kg | N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors |
US6586435B2 (en) * | 2000-09-19 | 2003-07-01 | Boehringer Ingelheim Pharma Kg | Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors |
ATE341538T1 (de) | 2000-09-19 | 2006-10-15 | Boehringer Ingelheim Pharma | Benzimidazolonderivate mit affinität zu serotonin-und dopaminrezeptoren |
WO2002041894A2 (en) | 2000-11-22 | 2002-05-30 | Abbott Laboratories | Selective dopamine d4 receptor agonists for treating sexual dysfunction |
GB0105893D0 (en) | 2001-03-09 | 2001-04-25 | Pfizer Ltd | Pharmaceutically active compounds |
DOP2002000364A (es) | 2001-03-28 | 2002-10-15 | Pfizer | Derivados de glutaramida sustituida con n-fenpropilciclopentilo como inhibidores de nep para fsad |
ES2267627T3 (es) * | 2001-05-11 | 2007-03-16 | Jurgen K. Dr. Beck | Flibaserina para el tratamiento de los trastornos del movimiento estrapiramidal. |
US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
ATE411021T1 (de) | 2001-07-18 | 2008-10-15 | Merck & Co Inc | Überbrückte piperidinderivate als melanocortin- rezeptor-agonisten |
JP4272056B2 (ja) | 2001-07-30 | 2009-06-03 | スペクトラム・ファーマシューティカルス・インコーポレーテッド | アリールピペラジンに連結したテトラヒドロインドロン及びプリン誘導体 |
EP1414816B1 (en) | 2001-08-02 | 2005-02-09 | BIDACHEM S.p.A. | Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments |
US7183410B2 (en) * | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
US20030060475A1 (en) * | 2001-08-10 | 2003-03-27 | Boehringer Ingelheim Pharma Kg | Method of using flibanserin for neuroprotection |
DE10138273A1 (de) | 2001-08-10 | 2003-02-27 | Boehringer Ingelheim Pharma | Arzneimittel mit neuroprotektiver Wirkung |
HUP0202719A3 (en) | 2001-08-21 | 2006-01-30 | Pfizer Prod Inc | Pharmaceutical compositions for the treatment of female sexual dysfunctions |
DE10149674A1 (de) * | 2001-10-09 | 2003-04-24 | Apogepha Arzneimittel Gmbh | Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung |
UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
DE10209982A1 (de) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma | Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe |
CN1655789A (zh) | 2002-05-22 | 2005-08-17 | 贝林格尔英格海姆法玛两合公司 | 新型含氟班色林多晶型物a的药物组合物 |
US20040048877A1 (en) * | 2002-05-22 | 2004-03-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions containing flibanserin |
US20060257482A1 (en) * | 2002-06-07 | 2006-11-16 | Patrik Kumar | Modified release, multiple unit drug delivery systems |
US20040116532A1 (en) * | 2002-09-13 | 2004-06-17 | Craig Heacock | Pharmaceutical formulations of modafinil |
US20040132697A1 (en) * | 2002-11-06 | 2004-07-08 | Pfizer Inc. | Treatment of female sexual dysfunction |
GB0225908D0 (en) | 2002-11-06 | 2002-12-11 | Pfizer Ltd | Treatment of female sexual dysfunction |
US20040147581A1 (en) | 2002-11-18 | 2004-07-29 | Pharmacia Corporation | Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy |
WO2004063864A2 (en) * | 2003-01-06 | 2004-07-29 | Laura Berman | Method and system for computerized sexual function assessment of female users |
WO2004069339A1 (en) | 2003-01-29 | 2004-08-19 | Psychogenics Inc. | Treatment for attention-deficit hyperactivity disorder |
US20050037983A1 (en) * | 2003-03-11 | 2005-02-17 | Timothy Dinan | Compositions and methods for the treatment of depression and other affective disorders |
US7644401B2 (en) * | 2003-04-24 | 2010-01-05 | International Business Machines Corporation | Executable file creation |
US20050065158A1 (en) * | 2003-07-16 | 2005-03-24 | Pfizer Inc. | Treatment of sexual dysfunction |
EP1653966A1 (en) | 2003-07-16 | 2006-05-10 | Pfizer Limited | Treatment of sexual dysfunction |
WO2005044238A1 (en) | 2003-11-07 | 2005-05-19 | Ranbaxy Laboratories Limited | Modified release solid dosage form of amphetamine salts |
US20050239798A1 (en) * | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the treatment of premenstrual and other female sexual disorders |
WO2005102342A1 (en) * | 2004-04-22 | 2005-11-03 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for the treatment of sexual disorders ii |
US20060014757A1 (en) * | 2004-07-14 | 2006-01-19 | Boehringer Ingelheim Pharmaceuticals | Method for the treatment of anorexia nervosa |
US20060025420A1 (en) * | 2004-07-30 | 2006-02-02 | Boehringer Ingelheimn International GmbH | Pharmaceutical compositions for the treatment of female sexual disorders |
JP2008511569A (ja) * | 2004-09-03 | 2008-04-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 注意欠如活動過多障害の治療方法 |
WO2006096439A2 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
CA2599937A1 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders |
JP2008538741A (ja) | 2005-03-04 | 2008-11-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 鬱病の治療用及び/又は予防用の医薬組成物 |
JP2008540356A (ja) * | 2005-05-06 | 2008-11-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 薬物乱用の治療方法 |
US20060258640A1 (en) * | 2005-05-13 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Use of Flibanserin in the treatment of chronic pain |
WO2006125041A1 (en) | 2005-05-19 | 2006-11-23 | Boehringer Ingelheim International Gmbh | Method for the treatment of sexual dysfunctions due to medical conditions |
EP1888071A1 (en) * | 2005-05-19 | 2008-02-20 | Boehringer Ingelheim International GmbH | Method for the treatment of drug-induced sexual dysfunction |
JP2009503020A (ja) | 2005-08-03 | 2009-01-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 肥満症の治療におけるフリバンセリンの使用 |
HU227490B1 (en) * | 2005-08-26 | 2011-07-28 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Sustained release pharmaceutical preparation containing carvedilol |
US20070123540A1 (en) * | 2005-10-29 | 2007-05-31 | Angelo Ceci | Sexual desire enhancing medicaments comprising benzimidazolone derivatives |
JP2009513604A (ja) | 2005-10-29 | 2009-04-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体 |
US20070105869A1 (en) * | 2005-11-08 | 2007-05-10 | Stephane Pollentier | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders |
NZ569984A (en) * | 2006-01-27 | 2011-06-30 | Eurand Inc | Drug delivery systems comprising weakly basic drugs and organic acids |
EP1988898A2 (en) * | 2006-02-18 | 2008-11-12 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin |
WO2007096300A1 (en) * | 2006-02-20 | 2007-08-30 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of urinary incontinence |
EP1991228A1 (en) * | 2006-02-28 | 2008-11-19 | Boehringer Ingelheim International GmbH | Treatment of prevention of valvular heart disease with flibanserin |
PE20080090A1 (es) * | 2006-05-09 | 2008-03-14 | Boehringer Ingelheim Int | Flibanserina para el tratamiento de trastornos post-menopausicos del deseo sexual |
DE602007004615D1 (de) | 2006-06-30 | 2010-03-18 | Boehringer Ingelheim Pharma | Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen |
US20090318469A1 (en) | 2006-07-14 | 2009-12-24 | Boehringer Ingelheim International Gmbh | Use of Flibanserin for the Treatment of Sexual Disorders in Females |
CA2657045A1 (en) * | 2006-07-14 | 2008-01-17 | Boehringer Ingelheim International Gmbh | Combinations of flibanserin with caffeine, process for their preparation and use thereof as medicaments |
JP2008040352A (ja) * | 2006-08-09 | 2008-02-21 | Seiko Epson Corp | 液体現像剤、液体現像剤の製造方法、画像形成方法、および画像形成装置 |
KR20090042967A (ko) * | 2006-08-14 | 2009-05-04 | 베링거 인겔하임 인터내셔날 게엠베하 | 플리반세린 제형 및 이의 제조방법 |
CL2007002214A1 (es) * | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
AU2007287639A1 (en) | 2006-08-25 | 2008-02-28 | Boehringer Ingelheim International Gmbh | Controlled release system and method for manufacturing the same |
WO2008116890A2 (en) | 2007-03-28 | 2008-10-02 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders |
-
2007
- 2007-08-10 AU AU2007287639A patent/AU2007287639A1/en not_active Abandoned
- 2007-08-10 CN CN201510127785.3A patent/CN104721168A/zh active Pending
- 2007-08-10 KR KR1020097006149A patent/KR20090045945A/ko not_active Application Discontinuation
- 2007-08-10 MX MX2009002031A patent/MX2009002031A/es active IP Right Grant
- 2007-08-10 WO PCT/EP2007/058302 patent/WO2008022932A2/en active Application Filing
- 2007-08-10 AR ARP070103545A patent/AR062321A1/es unknown
- 2007-08-10 JP JP2009525011A patent/JP5220746B2/ja active Active
- 2007-08-10 BR BRPI0716436A patent/BRPI0716436B8/pt active IP Right Grant
- 2007-08-10 EA EA200900270A patent/EA200900270A1/ru unknown
- 2007-08-10 CN CNA2007800316337A patent/CN101505736A/zh active Pending
- 2007-08-10 CA CA2661613A patent/CA2661613C/en not_active Expired - Fee Related
- 2007-08-10 EP EP07802563A patent/EP2056797A2/en not_active Withdrawn
- 2007-08-13 CL CL200702358A patent/CL2007002358A1/es unknown
- 2007-08-13 US US11/837,962 patent/US8512748B2/en active Active
- 2007-08-13 TW TW096129885A patent/TW200817053A/zh unknown
- 2007-08-13 PE PE2007001080A patent/PE20080738A1/es not_active Application Discontinuation
-
2008
- 2008-12-22 ZA ZA200810781A patent/ZA200810781B/xx unknown
-
2009
- 2009-01-08 NO NO20090100A patent/NO20090100L/no not_active Application Discontinuation
- 2009-02-19 IL IL197129A patent/IL197129A/en active IP Right Grant
- 2009-02-25 CO CO09019210A patent/CO6150131A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP5220746B2 (ja) | 2013-06-26 |
AR062321A1 (es) | 2008-10-29 |
CL2007002358A1 (es) | 2008-04-18 |
NO20090100L (no) | 2009-04-23 |
IL197129A0 (en) | 2009-11-18 |
BRPI0716436A2 (pt) | 2014-03-04 |
CN101505736A (zh) | 2009-08-12 |
ZA200810781B (en) | 2009-10-28 |
US8512748B2 (en) | 2013-08-20 |
JP2010501511A (ja) | 2010-01-21 |
WO2008022932A3 (en) | 2008-07-24 |
MX2009002031A (es) | 2009-03-06 |
BRPI0716436B1 (pt) | 2020-05-19 |
IL197129A (en) | 2014-08-31 |
TW200817053A (en) | 2008-04-16 |
KR20090045945A (ko) | 2009-05-08 |
CA2661613C (en) | 2016-01-26 |
BRPI0716436B8 (pt) | 2021-05-25 |
WO2008022932A2 (en) | 2008-02-28 |
AU2007287639A1 (en) | 2008-02-28 |
EP2056797A2 (en) | 2009-05-13 |
CN104721168A (zh) | 2015-06-24 |
EA200900270A1 (ru) | 2009-08-28 |
CO6150131A2 (es) | 2010-04-20 |
US20080069873A1 (en) | 2008-03-20 |
CA2661613A1 (en) | 2008-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20080738A1 (es) | Sistema de liberacion controlada y metodo para fabricarlo | |
DOP2016000132A (es) | Sistema de administración farmacologico | |
ES2536206T3 (es) | Parche medicinal | |
JOP20200145B1 (ar) | تركيبة عقار ذو إطلاق متأخر | |
BRPI0711784B8 (pt) | dispositivo de embolização construído de polímero expansível e seu método de preparação | |
UY35070A (es) | ?Sistemas de administración y formulación de fármacos de retención gástrica, y método para su preparación usando carbonato de calcio funcionalizado?. | |
AR070543A1 (es) | Sistema y metodo de fluido de tratamiento con rompedor oxidante | |
AR048862A1 (es) | Aparatos y metodos para el suministro transdermico de una vacuna antigripal | |
UY32151A (es) | Nuevo portador de agentes activos liberados de forma controlada | |
UY35071A (es) | ?formulación de forma farmacéutica sólida de desintegración veloz que comprende carbonato de calcio funcionalizado y método para su fabricación?. | |
AR072685A1 (es) | Composicion topica para el tratamiento de queratosis actinica | |
EA201000746A1 (ru) | Система трансдермальной доставки, способ трансдермального введения и способ изготовления системы трансдермальной доставки | |
AR070198A1 (es) | Elaboracion de enzimas lisosomales sulfatasa humanas activas y altamente fosforiladas y sus usos | |
AR061284A1 (es) | Metodo y aparato para administrar un conjunto de informacion relacionada con la conexion de comunicaciones | |
AR072359A1 (es) | Encapsulacion de agentes biologicamente activos | |
CO6321222A2 (es) | Una forma de dosificacion unitaria que comprende una matriz de pelicula delgada soluble en agua (oblea) que contiene un ingrediente activo | |
AR071737A1 (es) | Un metodo para producir geles de adapaleno | |
CL2013000163A1 (es) | Proceso para la preparacion de material de carbonato de calcio que comprende proveer al menos un material que contenga carbonato de calcio, proveer al menos una sal de un acido graso c5-c28, tratar el material poniendolo en contacto con dicho acido graso y obtener dicho material tratado superficialmente; material de carbonato de calcio; y su uso en el control de material organico en un medio acuoso. | |
GB2583855A8 (en) | Transmucosal delivery device and method of manufacturing same | |
PE20110876A1 (es) | Formulacion de deposito de octreotida con niveles de exposicion constantemente altos | |
BR112021017878A2 (pt) | Carbonato de magnésio com superfície reagida, sistema de liberação, formulação de cuidados domiciliares, métodos para preparar um carbonato de magnésio com superfície reagida e para preparar um sistema de liberação, e, uso de um carbonato de magnésio com superfície reagida e de um sistema de liberação | |
PE20070762A1 (es) | Forma de dosificacion osmotica con aspectos de liberacion controlada y de liberacion rapida | |
CL2013002633A1 (es) | Composicion de apresto que contiene un agente de apresto hidrofobico de papel y una poli(aminoamida) hidrofobicamente modificada, metodo para preparar una composicion de apresto, y metodo para apresto de papel. | |
WO2014124029A3 (en) | System and method for delivering protease inhibitors | |
ES2626069T3 (es) | Adhesivos multicomponente, fabricación de los mismos, y aplicaciones de los mismos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |